NASDAQ:ZYBT Zhengye Biotechnology (ZYBT) Stock Price, News & Analysis $1.37 0.00 (0.00%) Closing price 09/17/2026 04:00 PM EasternExtended Trading$1.40 +0.02 (+1.82%) As of 06:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Zhengye Biotechnology Stock (NASDAQ:ZYBT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zhengye Biotechnology alerts:Sign Up Key Stats Today's Range$1.32▼$1.3850-Day Range$0.70▼$8.0152-Week Range$0.62▼$10.12Volume34,429 shsAverage Volume61,018 shsMarket Capitalization$64.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Zhengye Biotechnology Group Co., Ltd. (NASDAQ: ZYBT) is a China-based biotechnology company focused on the research, development, manufacture and sale of biological products for animal use. The company serves the veterinary and animal-health markets, with products intended to help prevent and manage infectious diseases in livestock and other animals. Its product portfolio is centered on veterinary vaccines and related biological products. Zhengye Biotechnology also offers other animal-health products and services associated with disease prevention and herd health management. Its customers include participants in China’s animal husbandry and veterinary sectors. The company operates primarily in China through its operating subsidiaries and has been associated with the development and production of animal biological products. Publicly available information about its historical operations and leadership is limited, so further details regarding its management team and international activities are not included here.AI Generated. May Contain Errors. Read More Zhengye Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreZYBT MarketRank™: Zhengye Biotechnology scored higher than 19% of companies evaluated by MarketBeat, and ranked 839th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingZhengye Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageZhengye Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Zhengye Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioZhengye Biotechnology has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.37% of the float of Zhengye Biotechnology has been sold short.Short Interest Ratio / Days to CoverZhengye Biotechnology has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zhengye Biotechnology has recently decreased by 51.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZhengye Biotechnology does not currently pay a dividend.Dividend GrowthZhengye Biotechnology does not have a long track record of dividend growth. News and Social Media2.8 / 5News SentimentN/A News SentimentZhengye Biotechnology has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.Search InterestOnly 1 people have searched for ZYBT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zhengye Biotechnology insiders have not sold or bought any company stock.Percentage Held by InstitutionsZhengye Biotechnology has minimal institutional ownership at this time.Read more about Zhengye Biotechnology's insider trading history. Receive ZYBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zhengye Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZYBT Stock News HeadlinesZhengye Biotechnology Holding Ltd (ZYBT)August 28, 2026 | ru.investing.comZhengye Biotechnology Regains Nasdaq Minimum Bid Price ComplianceAugust 6, 2026 | tipranks.comPresident Trump’s new AI tirade hurting GOP?President Trump says AI regulation will not stop what he calls the greatest economic engine in history, bigger than oil, gold, diamonds, or the internet. Meanwhile, The New Republic reports Republicans are eager to rein in AI ahead of the midterms. Whitney Tilson, the analyst CNBC once called The Prophet for calling the dot-com crash, the Bear Stearns and Lehman collapses, and the 2009 market bottom, says a new divide begins in 100 days with major implications for portfolios. Tilson lays out what he believes could separate winning and losing portfolios over the next six months.September 18 at 1:00 AM | Stansberry Research (Ad)Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up TodayAugust 5, 2026 | quiverquant.comQZhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | BenzingaJuly 23, 2026 | benzinga.comZhengye Biotechnology Addresses Unusual Nasdaq Trading ActivityJuly 21, 2026 | tipranks.comZhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)July 21, 2026 | msn.comZhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading ActivityJuly 21, 2026 | quiverquant.comQSee More Headlines ZYBT Stock Analysis - Frequently Asked Questions How have ZYBT shares performed this year? Zhengye Biotechnology's stock was trading at $1.15 on January 1st, 2026. Since then, ZYBT stock has increased by 19.1% and is now trading at $1.37. When did Zhengye Biotechnology IPO? Zhengye Biotechnology (ZYBT) raised $6 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 1,500,000 shares at a price of $4.00 per share. Kingswood Capital Partners acted as the underwriter for the IPO. How do I buy shares of Zhengye Biotechnology? Shares of ZYBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ZYBT's financial health is in the Yellow zone, according to TradeSmith. ZYBT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZYBT Previous SymbolNASDAQ:ZYBT CIK1975641 Webwww.jlzybio.com Phone86-13844801919FaxN/AEmployees269Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.03 Current Ratio1.14 Quick Ratio0.82 Sales & Book Value Annual Sales$16.64 million Price / Sales3.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book1.47Miscellaneous Outstanding Shares47,390,000Free FloatN/AMarket Cap$64.92 million OptionableN/A Beta-2.56 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ZYBT) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredGold Miners Post Record Cash Flow Even as Prices Pull BackThe four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...Golden Portfolio | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...Monument Traders Alliance | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZYBT Stock Alerts